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ABSTRACT
Many low-penetrance breast cancer susceptibility
loci are found to be located in non-protein-coding
regions, suggesting their involvement in gene
expression regulation. We identified the human/
rat-conserved breast cancer susceptibility locus
MCS5A/Mcs5a. This locus has been shown to
act in a non-mammary cell-autonomous fashion
through the immune system. The resistant
Mcs5a allele from the Wistar–Kyoto (WKy) rat
strain consists of two non-protein-coding genetic
elements that must be located on the same chromo-
some to elicit the phenotype. In this study, we show
the presence of a conserved higher order chromatin
structure in MCS5A/Mcs5a located in between the
synthetically interacting genetic elements. The
looped elements are shown to be bound by CTCF
and cohesin. We identify the downregulation of
Fbxo10 expression in T cells as a strong candidate
mechanism through which the interacting genetic
elements of the resistant Mcs5a allele modulate
mammary carcinoma susceptibility. Finally, we
show that the human MCS5A polymorphisms
associated with breast cancer risk are located at
both sides of the looped structure and functionally
interact to downregulate transcriptional activity,
similar to rat Mcs5a. We propose a mechanistic
model for MCS5a/Mcs5a in which a CTCF-
mediated insulator loop encompassing the
TOMM5/Tomm5 gene, resides in between and
brings into closer physical proximity the synthetic-
ally and functionally interacting resistant genetic
variants.
INTRODUCTION
The risk of developing breast cancer involves the inter-
action between a woman’s inherited genetics and her en-
vironment. The genetic component of risk for most
common forms of breast cancer deﬁnes it as a complex
trait consisting of numerous susceptibility alleles and their
interactions. Approximately 25 of such alleles have been
identiﬁed thus far using genome-wide association studies
(GWAS) and comparative genetics and each is associated
with a low relative risk (1–10). Currently, a major open
question regarding these low-penetrance susceptibility
alleles is deﬁning their function in regard to breast
cancer etiology. The great majority of these alleles are
non-protein-coding, which implies that they may
modulate gene expression regulation. For example, the
alleles of a breast cancer risk variant in the second
intron of FGFR2 have been shown to differentially
regulate its expression (11). For the vast majority of
low-penetrance breast cancer susceptibility alleles, it
remains unclear if these are involved in gene expression
regulation and what their target genes may be.
Understanding mechanistically how these alleles
modulate breast cancer susceptibility could go beyond
population-based screening and lead to intervention
strategies for cancer prevention and therapy.
The non-protein-coding locus Mcs5a/MCS5A modu-
lates breast cancer susceptibility in both rats and women
(5). We identiﬁed this locus via a comparative genetics
approach consisting of linkage analysis in the backcross
progeny of the mammary carcinoma susceptible Wistar–
Furth (WF) rat strain and the resistant Wistar–Kyoto
(WKy) rat strain (12), subsequent genetic ﬁne-mapping
using congenic recombinant rat lines (13,14), and a case–
control association study using variants in the human
orthologous locus (5). When the resistant allele of
Mcs5a from the WKy rat strain is introgressed into the
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 50% reduction in mammary carcinoma multiplicity is
observed (5). The resistant allele acts in a non-mammary
cell-autonomous manner, during early mammary carcin-
oma progression through the immune system (15). We
have also shown that the presence of the resistant Mcs5a
allele is associated with T-cell homeostasis and functions
(15). Speciﬁcally, T cells of the Mcs5a resistant congenic
line show an increased mitogen-induced proliferation po-
tential and Th1 cytokine production, suggesting that the
Mcs5a allele exerts its effect on mammary carcinoma sus-
ceptibility through T cells (15). Mcs5a consists of two
non-protein-coding, synthetically interacting elements
(Mcs5a1, Mcs5a2), which have to be located on the
same chromosome to elicit the resistance phenotype (5).
The variants associated with breast cancer risk in women
are located in the human orthologous loci, MCS5A1 and
MCS5A2, respectively, at a distance of  60kb of each
other (5). Although identiﬁed by comparative genetics,
the MCS5A variants resemble GWAS-identiﬁed risk
alleles as the risk-associated polymorphisms are
non-protein-coding, are common in the population and
display low-genetic penetrance. The risk-associated
variant in MCS5A1 marked by single nucleotide poly-
morphism (SNP) rs6476643 has four correlated poly-
morphisms. These are located in a  5.7-kb region
around the CpG island that is associated with a predicted
promoter of FBXO10, a gene encoding the
uncharacterized E3 ubiquitin ligase F-box protein 10.
Similarly, the MCS5A2 variant marked by SNP
rs2182317 encompasses a total of 15 correlated poly-
morphisms spanning  26.1kb. These are located around
the CpG island that is associated with the predicted
promoter of the FERM and PDZ domain containing 1
gene, FRMPD1. We have shown previously that
between susceptible congenic control and Mcs5a resistant
congenic rats, Fbxo10 and Frmpd1 are differentially ex-
pressed in the thymus and spleen, respectively, and not
in the mammary gland (5). A third gene in the MCS5A
locus, the translocase of the outer mitochondrial
membrane5 gene, TOMM5, is not directly associated
with the breast cancer risk variants of MCS5A1 and
MCS5A2, but is located in the 60kb of sequence that sep-
arates them. SNP rs2182317 in MCS5A2 has recently been
shown to be among the most signiﬁcant of a list of 710
candidate breast cancer risk alleles and to modify risk to
both Estrogen Receptor-positive and -negative breast
cancer (4).
The availability of both human cell based and congenic
rat models allows us to address several mechanistic ques-
tions regarding the Mcs5a/MCS5A breast cancer suscep-
tibility alleles. First, we mechanistically address the
observation that the mammary carcinoma resistance
phenotype requires two genetic Mcs5a elements, separated
by Tomm5, to synthetically interact on the same chromo-
some. Next, we show that the synthetic interaction is also
required for downregulation of the transcript levels of
Fbxo10 in the thymus and in various sorted T-cell popu-
lations. Finally, we show that the resistant alleles of the
human breast cancer risk-associated variants could func-
tionally interact to downregulate transcriptional activity,
resembling transcriptional regulation of Fbxo10 by the
interacting genetic elements of the resistant rat Mcs5a
allele.
MATERIAL AND METHODS
Animals
The congenic rat lines were established and maintained in
an AAALAC-approved facility as previously published
(14). All animal protocols were approved by the
University of Wisconsin Medical School Animal Care
and Use Committee. Congenics are deﬁned as genetic
lines developed on a WF,susceptible genetic background
and carrying the selected WKy,resistant Mcs5a alleles.
The resistant congenic line WF.WKy-Mcs5a (‘Mcs5a’,
line WW) with a decreased 7,12- dimethylbenz(a)anthra-
cene (DMBA)-induced mammary carcinoma susceptibility
phenotype is WKy-homozygous at the entire Mcs5a locus
(5). The susceptible congenic control line WF.WKy
(‘susc.’) is WF-homozygous at Mcs5a and all other
identiﬁed Mcs loci. The susceptible congenic lines
WF.WKy-Mcs5a1 (‘Mcs5a1’, line B3) and WF.WKy-
Mcs5a2 (‘Mcs5a2’, Line LL) are WKy-homozygous at
Mcs5a1 and Mcs5a2, respectively (5). For all experiments,
only female animals were used.
Flow cytometry, magnetic cell sorting and T-cell
activation
For the gene expression studies, cells were prepared for
immunostaining by submerging fresh thymus and/or
spleen tissues in cold ﬂow cytometry solution (FCS: PBS
with 2% FBS and 25mM HEPES). Tissues in 1ml cold
FCS were dispersed using a 50mM Medicon (BD
Biosciences) ﬁlter grinders and a BD Medimachine for
 1min. The resulting cell suspension was ﬁltered with
70mM Filcon (BD Biosciences) and centrifuged to pellet
cells. In sterile 12ml polystyrene round-bottom Falcon
tubes (BD Biosciences), cells were resuspended in cold
FCS (25 10
6 cells/ml) and immunostained at 4 C with
0.5mg antibody-conjugate per 10
6 cells (25mg each
antibody) for 30min. Monoclonal antibodies from BD
Biosciences included anti-rat CD3 (clone 1F4), CD45RA
(clone OX-33), CD4 (clone OX-35) and CD8a (clone
OX-8). Cells were washed 1  with 1ml cold FCS and
ﬁltered prior to ﬂow cytometry sorting on a
FACSVantageSE (BD Biosciences) at the University of
Wisconsin Flow Cytometry Core Facility. For chromatin
studies, the enrichment of CD3
+ T cells was done by
magnetic cell sorting. Single cell suspensions (in cold
FCS) of anonymous cryopreserved human peripheral
blood mononuclear cell samples and rat (red blood
cell-reduced) splenocytes were incubated with CD3 and
pan-T cell (OX-52) microbeads (Miltenyi), respectively.
The labeled cell suspension was loaded onto a
pre-equilibrated MACS cell separation column
(Miltenyi), washed and eluted according to the manufac-
turer’s recommendations. CD3
+ T-cell purity was
estimated by ﬂow cytometry to be >92%. For T cell
culturing and activation, 2 million lymphocytes from
spleen were stimulated with 1mg/ml Concanavalin A
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in 2ml RPMI medium containing 10% FBS for 24h at
37 C in a 95% air/5% CO2 atmosphere. Unstimulated
cells served as a control. Splenocytes were stained with
anti-T-cell microbeads (OX52, Miltenyi) and T cells were
sorted by positive selection using Easysep magnet (Stem
Cell Technologies). Purity of T cells was >90% as
determined by CD3 labeling and ﬂow cytometry.
Primary T-cell nucleofections with siRNAs
Nucleofections were carried out by following the Mouse
T-Cell Nucleofector Kit (Lonza) protocol. Brieﬂy, 2 10
6
T cells (from a pool of sorted splenic T cells with equal
contribution from four female Mcs5a resistant congenic
rats) were pelleted at low speed (10min, 90g) and resus-
pended in 100ml supplemented Nucleofector Solution.
Two nanomoles of the desired siRNAs (ON-
TARGETplus Non-Targeting, and ON-TARGETplus
SMARTpool CTCF; Dharmacon) were mixed in,
followed by nucleofection using program X-001 of the
Nucleofector II Device. The cells were cultured in
Nucleofection Media for 64–68h at 37 C in a 95% air/
5% CO2 atmosphere.
Chromosome conformation capture assay
Rat templates were prepared from T cells of six susceptible
congenic control, and six Mcs5a resistant congenic
animals. Human templates were prepared from three
T-cell samples. Approximately 5 10
6 T cells (or 2 10
6
for the siRNA experiments) were diluted in 40ml of PBS
and 1.7ml of 37% formaldehyde was added to ﬁx chro-
matin. The solution was allowed to ﬁx for 10min at room
temperature. To quench the reaction, 2.7ml of 2M glycine
was added to each tube and incubated for 5min at room
temperature, after which the tubes were placed on ice for
15min. To burst the cells and expose the ﬁxed chromatin,
the cells were centrifuged for 10min at 800g and resus-
pended in 0.5ml ice-cold lysis buffer, containing 10mM
Tris–HCl pH 8.0, 10mM NaCl, 0.2% Nonidet P-40
(NP-40), 1  protease inhibitors (Roche Applied
Science). The reaction was allowed to proceed on ice for
10min. The cells were gently lysed via dounce homogen-
ization using a tight pestle for 1min on ice. The reaction
sat on ice for 1min and homogenization was repeated for
30s. Next, the lysis buffer was removed, the nuclei were
washed in 0.5ml of 1  restriction enzyme buffer (NEB3;
New England Biolabs) and resuspended in 400mlo f1  
restriction enzyme buffer containing 0.1% SDS. This
mixture was incubated at 65 C for 10min. To sequester
SDS, Triton X-100 was thoroughly mixed in to a ﬁnal
concentration of 1%. To digest the DNA and obtain
cross-linked DNA fragments, 400U of BglII restriction
enzyme (New England Biolabs) was added. The reaction
was incubated overnight at 37 C under slow rotation. The
following day, SDS was added to a concentration of 2%.
The mixture was incubated at 65 C for 30min. The
ligation was done in a ﬁnal volume of 7.5ml, in the
presence of 50mM of Tris–HCl (pH 7.5), 10mM of
DTT, 10mM of MgCl2, 1% Triton X-100, 0.11mg/ml of
BSA, 1.07mM of ATP and 4000U of T4 DNA ligase
(New England Biolabs). The reactions were incubated at
16 C for 4h. To remove any residual proteins, 33mlo f
Proteinase K (15mg/ml; Roche Applied Science) was
added to each tube and incubated at 65 C overnight. An
additional 33ml of Proteinase K was added and the
mixture was incubated for 2h at 42 C. Finally, the
ligated DNA products were isolated using two phe-
nol:chloroform (1:1) extractions, and one chloroform ex-
traction in 7.5ml volume, followed by ethanol
precipitation. The pellets were resuspended in 1ml of
dH2O containing RNAse A (Roche Applied Science) in
a ﬁnal concentration of 10mg/ml. Following a 30min in-
cubation at room temperature, ﬁnal phenol:chloroform
and chloroform extractions were performed, followed by
ethanol precipitation. The pelleted DNA was washed ﬁve
times with 70% ethanol and dissolved in 400mlo fd H 2O.
The concentration of template from each individual tissue
sample was determined by agarose gel electrophoresis,
quantifying the template band by comparing it to the
known amount of the highest band of a 1-kb DNA
ladder (NEB). Equal amounts of each template were
pooled. All pools were diluted to the same concentration.
The amount to use in a PCR detection reaction (1ml) was
determined empirically. For preparing the control DNA
templates, Bacterial Artiﬁcial Chromosome (BAC) DNA
templates corresponding to the human MCS5A and rat
Mcs5a regions (human: RP11-656G18; rat: CH230-
298P15 and CH230-303N12) were obtained from
Children’s Hospital Oakland Research Institute
(CHORI). The BAC DNA was isolated using a Plasmid
Maxi kit (QiaGen) and 500ng was digested overnight at
37 C using 5U of BglII restriction enzyme (NEB). The
restriction fragments were recovered using phenol:chloro-
form and chloroform extractions, followed by ethanol pre-
cipitation. The digested BAC DNA was religated by
adding 5mlo f1 0   ligation buffer and 2U of T4 DNA
Ligase (Roche Applied Science). The mixture was
incubated overnight at 16 C. The religated fragments
were recovered by phenol:chloroform and chloroform ex-
traction, followed by ethanol precipitation. The DNA
concentration was measured by nanodrop and diluted to
10ng/ml. A working stock of 1:1000 dilution was prepared.
The amount to use in a reaction (0.02ml) was empirically
determined. Empirically determined DNA template was
added to each reaction well and stored on ice. The PCR
mixture was prepared on ice, and mixed into the
pre-cooled DNA templates. The reaction was done in
the presence of 1  Herculase reaction buffer, 0.2mM of
each NTP, 0.4mM of each primer, 0.3ml of Herculase
Enhanced polymerase (5U/ml; Stratagene) in a total
volume of 25ml. Primer sequences are listed in
Supplementary Table S1. The PCR was performed using
a Peltier Thermocycler (PTC-225; MJ Research), using the
following cycling conditions: 95 C for 1min, 35 cycles of
95 C for 30s, 60 C for 30s, 72 C for 20s, followed by a
ﬁnal extension of 72 C for 8min. When the program was
complete, 5mlo f6   loading buffer (15% w/v Ficoll-400,
0.25% w/v Xylene Cyanol FF) was added to the reaction
and 12ml of each reaction was analyzed by agarose gel
electrophoresis. The gels were stained by soaking in a
1mg/ml ethidium bromide solution for 10min, and
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UV-exposure using the Gel Doc XR system (Biorad).
PCR band intensity was quantiﬁed using ImageQuant
software (GE Healthcare).
Chromatin immunoprecipitation
The JURKAT (clone E6-1; CD4
+leukemic T-lymphocytic
cell line) cell line was obtained from ATCC and grown in
GIBCO RPMI-1640 media (Invitrogen) supplemented
with 10% decomplemented Hyclone Fetal Bovine Serum
(FBS; Thermo Scientiﬁc) and 1% Penicillin/Streptomycin
(Invitrogen). JURKAT cells were cultured to a density of
 3 10
6 cells/ml. Roughly 2 10
6 JURKAT cells or
splenic T cells from female susceptible congenic control
and Mcs5a resistant congenic rats were ﬁxed using formal-
dehyde to a ﬁnal concentration of 1% at room tempera-
ture for 10min. Fixation was followed by centrifugation
(5min, 800g) to pellet the cells. The cells were washed
twice with PBS. The chromatin immunoprecipitation
(ChIP) assay was done using the ChIP Assay Kit
(Upstate/Millipore) following manufacturer’s recommen-
dations with one exception: the SDS lysis buffer was
reconstituted to contain 0.1% of SDS instead of 1%.
For one assay 4 10
6 cells were resuspended in 200mlo f
SDS-lysis buffer. Chromatin was sheared to 200- to
1000-bp fragments by sonication using three pulses of
10s on the third power level of a Branson soniﬁer (Cell
disruptor 185; Branson). Roughly 1% of the sonicated
chromatin was set aside as the input (positive control)
sample. Immunoprecipitations were done on the remain-
der of the sonicated chromatin using the following
antibodies: rabbit monoclonal to CTCF (07–729;
Millipore), rabbit polyclonal to Rad21 (cohesin; ab992;
Abcam), and rabbit control IgG (negative control;
ab46540; Abcam). Immunoprecipitations and input
DNA were recovered by phenol:chloroform and chloro-
form extractions, followed by ethanol precipitation.
Input- and immunoprecipitation-recovered DNAs were
tested in a dilution series as templates in detection
PCRs. Empirically determined DNA template was added
to each reaction well and stored on ice. The PCR mixture
was prepared on ice, and mixed into the pre-cooled DNA
templates. The reaction was done in the presence of 1 
Herculase reaction buffer, 0.2mM of each NTP, 0.4mMo f
each primer, 0.3ml of Herculase Enhanced polymerase
(5U/ml) in a total volume of 20ml. The PCR was per-
formed using a Peltier Thermocycler, using the following
cycling conditions for the human primers: 95 C for 1min,
32 cycles of 95 C for 30s, 58 C for 30s, 72 C for 15s,
followed by a ﬁnal extension of 72 C for 3min, and the
following cycling conditions for the rat primers: 95 C for
1min, 32 cycles of 95 C for 30s, 56 C for 30s, 72 C for
15s, followed by a ﬁnal extension of 72 C for 3min.
Primer sequences are listed in Supplementary Table S1.
When the program was complete, 5mlo f6   loading
buffer (15% w/v Ficoll-400, 0.25% w/v Xylene Cyanol
FF) was added to the reaction and 10ml of each reaction
was analyzed by agarose gel electrophoresis. The gels were
stained by soaking in a 1mg/ml ethidium bromide solution
for 10min, and destained in dH2O for 10min. Image was
taken under UV exposure.
RNA extraction and quantitative real-time PCR
Congenic female rats (11weeks of age) of line WF.WKy
(susc.), line WW (Mcs5a), line B3 (Mcs5a1) and line LL
(Mcs5a2) were used as tissue donors. RNA was extracted
from snap-frozen tissues and sorted cell samples using the
MagMax-96 Total RNA isolation kit (Ambion) according
to manufacturer’s directions. To synthesize cDNA from
500ng total RNA treated with TURBO-free DNase
(Ambion), the reverse transcriptase Superscript II kit
(Invitrogen) was used according to manufacturer’s direc-
tions. Quantitative real-time PCR was used to quantify
transcript levels. TaqMan quantitative PCR primers and
probes (available in Supplementary Table S1) were either
designed using Primer Express v 2.0 (ABI/Applied
Biosystems) according to developer’s speciﬁcations, or
ordered as made-to-order assays (Fbxo10
Rn01439970_m1; Tomm5 Rn01436622_g1; Mcart1
Rn01764629_g1; Dcaf10 Rn01764617_m1; ABI/Applied
Biosystems). A microliter of cDNA ( 12.5ng RNA
equivalent cDNA) was used in a 16ml TaqMan QPCR
reaction. Reaction components were 1  TaqMan Buffer
A (Applied Biosystems), 5.5mM MgCl2, 400mM each
dATP, dCTP, dGTP, dTTP and 0.4U Taq Gold DNA
Pol (ABI). For the custom designed assays, 500nM each
experimental primer, 200nM TaqMan experimental
probe, 60nM each Gapdh primer, 120nM rodent Gapdh
probe, were used per reaction. For the made-to-order
assays, 0.8ml of the experimental assay and 0.4ml of the
ActB standard assay were used per reaction. Cycling con-
ditions were 50 C for 2min, 95 C for 10min, followed by
40 cycles of 95 C for 15s and 60 C for 1min. FAM
(Fbxo10, Frmpd1, Tomm5 probe) and VIC (Rodent
Gapdh or ActB probe, ABI) ﬂuorescence values were
measured in real-time on an ABI 7900 real-time PCR
machine using ABI SDS v2.2 software. Quantities of tran-
scripts were measured by comparison of Ct values with a
standard curve calculated from serial dilutions made from
reverse transcriptase (RT) reactions that contained 2mgo f
total RNA. Sample measurements are an average of four
replicates. Sample measurements were normalized by
dividing the gene-speciﬁc transcript quantity over the
rodent Gapdh or ActB transcript quantity detected in the
same reaction. Ratios were scaled to the ratio of the sus-
ceptible congenic control sample from the same experi-
ment. Data were analyzed using Kruskal–Wallis or
Mann–Whitney non-parametric tests. Transcript levels
were only statistically compared if the samples were run
in the same assay plate.
50 RNA ligase mediated-rapid ampliﬁcation of cDNA
ends (50 RLM-RACE)
To localize the exact transcriptional start site (TSS) of the
Fbxo10 transcripts, the 50 RLM-RACE assay was per-
formed using the FirstChoice RLM-RACE kit (Ambion)
following manufacturer’s recommendations. Thymic
or splenic total RNA from ﬁve susceptible congenic
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Equal amounts of RNA (as determined by Nanodrop
quantiﬁcation) were pooled and 10mg of each pool was
used as input RNA into the reaction. To identify the
human FBXO10 TSS, 10mg total RNA from breast,
thymus or spleen (Ambion) were used as input. To
amplify the 50-ends of the Fbxo10/FBXO10 transcripts, a
nested PCR was performed with the gene-speciﬁc primers
(available in Supplementary Table S1) annealing to the
translational start codon (ATG)-containing exon that is
presumably shared by all Fbxo10/FBXO10 transcripts.
A typical PCR product yielded multiple bands on an
agarose gel, indicative of multiple TSS. The products
were blunt-cloned using the ZEROBLUNT vector
system (Invitrogen) for subsequent resequencing. In
total, 150 individual rat thymus or spleen TSS products
and 54 individual human thymus, spleen or breast TSS
products were analyzed by resequencing. The subcloned
sequences were identiﬁed by performing BLAT searches
using the UCSC genome browser.
Vector construction, transient transfection, luciferase
assays and Bradford assays
Genomic fragments with the appropriate polymorphisms
were ampliﬁed from MCS5A1 and MCS5A2 heterozygous
genomic DNA using the Platinum HiFi Taq polymerase
(Invitrogen) and primers containing the restriction sites
(BamHI, SalI) used for cloning (available in
Supplementary Table S1). First, the FBXO10-TSS con-
structs were made by inserting the BamHI-, SalI-
digested genomic FBXO10-TSS fragment using the XhoI
and BglII site located upstream of Luc
+ in pGL3-Basic
(Promega). The S and R versions of the FBXO10-TSS
construct were digested with BamHI and SalI to insert
the BamHI-, SalI-digested genomic fragments containing
the MCS5A2 polymorphisms. To ensure integrity, all con-
structs underwent visual inspection by restriction enzyme
digestion with NotI and SacI (Supplementary Figure S2),
as well as resequencing of both inserts. The JURKAT
(clone E6-1; CD4
+ leukemic T-lymphocytic cell line) cell
line was obtained from ATCC and grown in GIBCO
RPMI-1640 media (Invitrogen) supplemented with 10%
decomplemented Hyclone Fetal Bovine Serum (FBS;
Thermo Scientiﬁc) and 1% Penicillin/Streptomycin
(Invitrogen). JURKAT cells were cultured to a density
of  3 10
6 cells/ml. The cells were diluted into fresh
prewarmed RPMI/FBS media to a density of 0.5 10
6
cells/ml. A total of 500ml cells (approximately 250000
cells) were distributed into each well of a 24-wells
culture plate. The cells were allowed to rest for at least
3h. Transient transfection was performed using LTX
Lipofectamine reagent (Invitrogen) according to manufac-
turer’s recommendations. The DNA concentration of each
construct was veriﬁed before each transfection. All DNA
concentrations were between 90 and 110ng/ml. For each
transfection, 500ng of construct DNA was diluted with a
mixture of 100ml GIBCO OPTI-MEM reduced serum
media (Invitrogen), 5ml of PLUS reagent (Invitrogen)
and 5ng of Renilla internal control vector pRL-TK
(Promega). Following a 5-min incubation at room
temperature, 5ml of LTX Lipofectamine was added.
The transfection solution was mixed by pipetting
up-and-down, followed by a 30-min incubation at room
temperature. A total of 100ml of the transfection solution
was added to each well containing the cells. The cells and
the transfection solution were mixed by gently shaking the
plate in multiple directions. The cells were cultured for
44–48h. The Luciferase assay was performed using the
Dual-Luciferase Reporter Assay kit (Promega) according
to the manual. The cells were harvested, spun down and
washed with PBS. The cell pellet was lysed in 100ml1  
Passive Lysis Buffer and incubated at room temperature
for 15min. An amount of 20ml of the lysate was measured
in a 12 75mm disposable culture tube (Fisher Scientiﬁc).
Each transfection was measured three times, using a
Luminometer Monolight 3010 (BD Biosciences). The
Luminometer was set as follows: inject 100ml of the
Luciferase substrate, 2s delay, 10sof measuring time,
inject 100ml of the Stop-and-Glo solution, 2sdelay,
10smeasuring time. The remainder of each lysates was
used to quantify total protein content using Bradford
assays. To determine total protein content of the lysate,
5ml of the lysate was mixed with 250ml1   QuickStart
Bradford Dye reagent (Biorad) in a 96-well ﬂat bottom
titer plate. The plate was incubated for 15min at room
temperature. The optical density (OD) at 560nm wave-
length was determined using a Spectrophotometer for
microtiter plates. The OD was correlated to a standard
curve derived from a dilution series using Bovine Serum
Albumine (BSA). Relative Luciferase/Renilla activity of
each construct was determined by dividing the
Luciferase/Bradford ratio over the Renilla value. Each
construct was subsequently normalized against the
relative Luciferase activity of the pGL3-control construct
present in each 24-well plate. The SS and RR version of
each construct were always present in the same 24-well
plate. The normalized values for the SS and RR version
of each construct from at least six transfections were
tested for a signiﬁcant difference using the Wilcoxon
rank sum test.
RESULTS
The Chromosome conformation capture assay identiﬁes
a conserved higher order chromatin loop within
Mcs5a/MCS5A
To investigate if chromatin looping could provide a mech-
anistic basis for the synthetic (genetic) interaction between
the genetic elements in Mcs5a1 and Mcs5a2, we applied
the chromosome conformation capture (3C) assay to the
rat and human Mcs5a/MCS5A locus (Figure 1A). The 3C
assay measures the relative (looping) interaction frequency
of crosslinking captured, enzymatically digested (BglII),
ligated chromatin fragments (16). For the rat Mcs5a
locus, the ﬁxed fragment was initially chosen to encom-
pass the genomic region orthologous to the 5.7-kb region
in the human genome harboring the correlated poly-
morphisms in MCS5A1 that are associated with breast
cancer risk (5). This ﬁxed fragment also contained the
136 Nucleic Acids Research, 2012,Vol. 40,No. 1Figure 1. Analysis of the higher order chromatin structure of rat and human Mcs5a/MCS5A.( A) Maps of the rat and human Mcs5a/MCS5A locus.
The relative position of Mcs5a1/MCS5A1, Mcs5a2/MCS5A2, all BglII restriction site, the transcripts Fbxo10/FBXO10, Tomm5/TOMM5 and
Frmpd1/FRMPD1, and the human breast cancer risk-associated variants is indicated. The primers matching the ﬁxed fragments used to generate
panels (B–E) are indicated by black vertical triangles. (B–D) 3C proﬁles of the Mcs5a locus in T cells of susceptible congenic control (susc.)
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(continued)CpG island associated with a predicted Fbxo10 promoter.
Relative interaction frequencies with the majority of BglII
fragments in Mcs5a were determined. Restriction frag-
ments located close to the ﬁxed fragment yielded a high
relative interaction frequency that decreased with
increasing genomic distance, indicative of random
ligation, but no looping (Figure 1B). Similarly, taking a
nearby BglII fragment (two BglII fragments equaling
 5kb upstream of the one containing the predicted
Fbxo10 promoter) as the ﬁxed fragment yielded no
looping (Supplementary Figure S1A and B). However,
when the ﬁxed fragment was shifted further upstream
(ﬁve BglII fragments equaling  10kb) of the one contain-
ing the predicted Fbxo10 promoter, two areas of locally
increased relative interaction frequency were identiﬁed, in-
dicative of looping (Figure 1C). Both looping areas are
located in the Mcs5a2 region, close to the Mcs5a1–
Mcs5a2 border. For conﬁrmation, a BglII fragment in
the ﬁrst looping area was chosen as the ﬁxed fragment.
The proﬁle showed the same areas of looping, namely the
previous ﬁxed fragment in Mcs5a1 and the second
looping area in Mcs5a2 (Figure 1D). Furthermore,
none of the loops appeared to be inﬂuenced by the sus-
ceptible or resistant Mcs5a genotype as the 3C proﬁles
show the same trends. All 3C experiments described
above were performed on primary T cells, as we
consider this a speciﬁc cell type of Mcs5a activity (15).
The spatial organization of the Mcs5a locus in the
mammary gland was found to be similar to the proﬁle
in T cells, as the same regions were found to be involved
in the chromatin looping interactions (Supplementary
Figure S1C and D).
The 3C proﬁle of the orthologous human MCS5A locus
was found to be highly similar to rat Mcs5a (Figure 1E).
No looping was found with the ﬁxed fragment containing
the MCS5A1 correlated polymorphisms that associate
with breast cancer risk (Figure 1E). This ﬁxed fragment
also contained the CpG island associated with the pre-
dicted FBXO10 promoter. With the ﬁxed fragment
shifted upstream (two BglII fragments equaling  10kb)
of the CpG island associated with the predicted FBXO10
promoter, two areas of looping were found to be located
in MCS5A2, close to the MCS5A1–MCS5A2 border
(Figure 1E). The similarities in the 3C proﬁles of the rat
and human Mcs5a/MCS5A suggest that the higher order
chromatin structure of Mcs5a/MCS5A is evolutionary
conserved.
CTCF and cohesin binding is conﬁrmed in all interacting
chromatin looping fragments
The position of the looping elements at either side of the
Tomm5/TOMM5 gene, thus spatially isolating this gene,
suggests a function as an insulator loop. The CCCTC
-binding factor (CTCF) protein is widely known for its
role as a vertebrate insulator protein (17). Additionally,
CTCF has been shown to be essential for long-distance
enhancer–promoter looping (18). Recently, the cohesin
protein complex has also been shown to be essential for
long-range chromatin looping in the developmentally
controlled IFNG locus (19). We sought to investigate
whether CTCF and/or cohesin binding could also
underlie the observed higher order chromatin structure
of MCS5A/Mcs5a. Using a ChIP assay with antibodies
against CTCF and Rad21, a DNA-binding subunit of
the cohesin complex, association of both CTCF and
cohesin to all three interacting chromatin looping frag-
ments was conﬁrmed in both a human T-lymphocytic
cell line (JURKAT, Figure 2A) and rat primary T cells
(Figure 2B). No evidence of CTCF or cohesin binding was
found in a location outside of the looping fragments
(Figure 2A and B). CTCF binding was conﬁrmed on a
site in the H19 locus previously shown to bind CTCF in
human (20) and rat (21). The location of the CTCF-
binding site in the looping fragment MCS5A1 and the
ﬁrst looping fragment in MCS5A2 coincides with CTCF
binding previously identiﬁed in a genome-wide ChIP-seq
study (22).
To test if CTCF is necessary for the higher order chro-
matin structure, a short-interfering RNA (siRNA)
approach was undertaken to deplete primary rat T cells
with CTCF. Nucleofection of siRNA against CTCF
resulted in a signiﬁcant reduction of CTCF transcript
level (measured after 64–68h) as compared with
nucleofection with control siRNAs (Figure 2C).
Interestingly, the transcript level of Tomm5, the gene
residing within the looped structure was also signiﬁcantly
reduced after nucleofection with siRNAs against CTCF
(Figure 2D). The transcript levels of a housekeeping
gene, Gapdh and two genes close to the Mcs5a locus,
Mcart1 and Dcaf10 were not affected by CTCF depletion
(Figure 2D). Using the ChIP assay a reduction of enrich-
ment of the Mcs5a1 3C looping fragment in the cells
nucleofected with siRNAs against CTCF as compared
with the cells nucleofected with control siRNAs was
observed, consistent with CTCF depletion (Figure 2E).
Figure 1. Continued
and Mcs5a resistant congenic (Mcs5a) rats. The position of the ﬁxed fragments is indicated with a black bar and F, and the primer within the ﬁxed
fragment is indicated with a vertical triangle. In (B) the ﬁxed fragment contains the CpG island associated with the predicted promoter of Fbxo10 in
Mcs5a1. In (C) the ﬁxed fragment is located ﬁve BglII restriction fragments ( 10kb) upstream of the previous ﬁxed fragment that contains the CpG
island in Mcs5a1. In (D) the ﬁxed fragment was located in the ﬁrst looping fragment in Mcs5a2.( E) Comparison of the rat and human Mcs5a/
MCS5A 3C proﬁle. Dashed lines represent the 3C proﬁle with the ﬁxed fragment containing the predicted Fbxo10/FBXO10 promoter in Mcs5a1/
MCS5A1 and does not display looping to Mcs5a2/MCS5A2. In the human, this ﬁxed fragment also contains the four correlated MCS5A1 poly-
morphisms associated with breast cancer risk. Solid lines represents the 3C proﬁle with the ﬁxed fragment located ﬁve (rat) or two (human) BglII
restriction fragments ( 10kb) upstream of the BglII fragment containing the predicted Fbxo10/FBXO10 promoter in Mcs5a1/MCS5A1. The chro-
matin fragments in Mcs5a2/MCS5A2 looping to the ﬁxed fragment in Mcs5a1/MCS5A1 are indicated with PEAK 1 and PEAK 2. Graphed are the
average±SEM relative interaction frequencies of a ﬁxed BglII fragment with other BglII fragments in Mcs5a/MCS5A. The genomic distance (in
kilobases) represents the distance of the midpoint of a BglII fragment to the Mcs5a1/MCS5A1-Mcs5a2/MCS5A2 border.
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relative interaction frequency between the Mcs5a1 and
ﬁrst Mcs5a2 looping fragments and between the Mcs5a1
and second Mcs5a2 looping fragments was observed in the
cells nucleofected with siRNAs against CTCF, as
compared with cells nucleofected with control siRNAs
(Figure 2F). We conclude that CTCF is necessary for
the higher order chromatin structure of Mcs5a.
Disruption of this structure resulted in lower transcript
level of Tomm5.
Mcs5a controls the transcript level of Fbxo10 in T cells
We previously reported that the non-protein-coding resist-
ant Mcs5a allele is associated with lower Fbxo10 and
higher Frmpd1 transcript levels in thymus and spleen, re-
spectively (5), and that the resistance phenotype is
mediated by the immune system (15). Here, we explored
by quantitative real-time PCR using TaqMan assays, if
the difference in transcript levels of these two genes, like
the mammary carcinoma resistance phenotype, is
controlled by the two synthetically interacting genetic
Figure 2. CTCF and cohesin bind to the looping fragments in Mcs5a/MCS5A and CTCF is necessary for the higher order chromatin structure.
(A and B) The Mcs5a1/MCS5A1 and Mcs5a2/MCS5A2 loci are depicted as black lines. The light gray bars within the black lines are the CpG islands
associated with the promoters of the Fbxo10/FBXO10, Tomm5/TOMM5 and Frmpd1/FRMPD1 genes, respectively. The locations of the three
interacting chromatin looping fragments identiﬁed in the 3C assay are indicated by light gray blocks. In the human, the location of known
CTCF sites from a genome-wide CTCF ChIP-seq study is indicated (22). Amplicons within and outside the looping Mcs5a/MCS5A fragments,
as well as an amplicon in the H19 locus (as a positive control) were analyzed by PCR on CTCF (C), cohesin (R; Rad21) and IgG (I; negative
control) antibody immunoprecipitated chromatin samples, and an input (IN, positive control) sample, prepared from JURKAT cells (human) or
primary rat splenic T cells (rat). Each gel image is accompanied by a 100-bp DNA ladder of which the lower three bands (100, 200, 300bp) are
shown. CTCF and cohesin binding was found in all looping fragments and the H19 positive control locus, but not in the Mcs5a2 fragment not
located in a looping fragment. (C and D) Transcript level of CTCF, Tomm5, Gapdh, Mcart1 and Dcaf10 (normalized to ActB) measured 64–68h after
nucleofection of rat primary T cells with control siRNAs (siCONTROL; light gray bars) and siRNAs against CTCF (siCTCF; dark gray bars). The
transcript level of CTCF and Tomm5 was signiﬁcantly reduced (indicated with an asterisk) in the siCTCF-treated T cells. The transcript levels of the
housekeeping gene Gapdh and genes Mcart1 and Dcaf10 located adjacent to the Mcs5a locus were not affected. (E) ChIP analysis of CTCF binding
to the looping fragment in Mcs5a1 and the negative control fragment in Mcs5a2 in primary rat T-cells 64–68h after nucleofection with control
siRNAs and siRNAs against CTCF. CTCF binding to the Mcs5a1 looping fragment was reduced in the siCTCF-treated T cells. (F) 3C analysis of
the Mcs5a locus in primary rat T cells 64–68h after nucleofection with control siRNAs (light gray line) and siRNAs against CTCF (dark gray line).
The looping fragment in Mcs5a1 was taken as the ﬁxed fragment (indicated with a black bar and F). Looping of the ﬁxed fragment to the looping
fragments in Mcs5a2 was signiﬁcantly reduced (indicated with an asterisk) in the siCTCF-treated T cells.
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Frmpd1 transcript levels were compared between the
susceptible congenic control line (WF-homozygous at
Mcs5a), the Mcs5a resistant congenic line (WKy-
homozygous at Mcs5a) and the Mcs5a1 and Mcs5a2
susceptible congenic lines (WKy-homozygous at Mcs5a1
or Mcs5a2, respectively). The Fbxo10 transcript level was
signiﬁcantly reduced (P=0.01) in the thymus of the
Mcs5a congenic resistant animals and was not signiﬁcant-
ly different in thymus tissue from either the Mcs5a1 or
Mcs5a2 susceptible congenic lines when compared to the
susceptible congenic control line (Figure 3A). Thus,
having lower thymic Fbxo10 transcript levels required
the same synthetic interaction between Mcs5a1 and
Mcs5a2 as was necessary for the mammary carcinoma
resistance phenotype. Conversely, higher Frmpd1 tran-
script levels in the spleen did not require the synthetic
interaction, as the Mcs5a resistant congenic line, and
both Mcs5a1 and Mcs5a2 susceptible congenic lines
had higher splenic Frmpd1 transcript levels as
compared with the susceptible congenic control line
(Figure 3A).
Subsequently, Fbxo10 transcript levels were moni-
tored in various classes of sorted and unsorted thymocytes
(Figure 3B). The reduction in Fbxo10 transcript levels
associated with the resistant Mcs5a allele was
observed in unsorted (P=0.03), CD4
+CD8
+ (P=0.02),
CD4
+CD8
  (P=0.03) and CD4
 CD8
+ (P=0.002),
but not in CD4
 CD8
  thymocytes (P=0.77). The
Fbxo10 transcript level difference was also found in
CD3
+ T cells sorted from the spleen (P=0.001),
whereas other classes of sorted and unsorted
splenocytes did not display the differential transcript
levels (Figure 3C). The Fbxo10 transcript level difference
in splenic T cells persisted upon culturing (P=0.0003)
and concanavalin A (conA) stimulation (P=0.01;
Figure 3D).
C9ORF105/C9orf105 is a spliced transcript located in
the 60-kb sequence between the human MCS5A1 and
MCS5A2 risk-associated polymorphisms on the rat
Mcs5a1–Mcs5a2 border and was recently annotated as
the translocase of outer mitochondrial membrane 5
gene, TOMM5/Tomm5. We checked if the transcript
level of C9orf105 is associated with the resistant rat
Mcs5a allele in the immune system. Tomm5 transcript
levels were not different between susceptible congenic
control and Mcs5a resistant congenic rats in whole
spleen (P=0.18) and thymus (P=0.40) tissues
(Figure 3E). Similarly, in primary T cells sorted from
the spleen, Tomm5 was not differentially expressed
(P=0.94; Figure 3E). In cultured T cells from susceptible
congenic control and Mcs5a resistant congenic rats, the
transcript levels of Tomm5 were found to be different
(P=0.008; Figure 3F). In conA-stimulated cultured
T-cells Tomm5 transcript levels were not found to be dif-
ferent (P=0.95) between the Mcs5a genotypes.
Interestingly, in conA-stimulated T cells, Tomm5 tran-
script levels were found to be strongly increased
( 3-fold) when compared to unstimulated cultured
T-cell samples from the rat lines harboring both Mcs5a
genotypes (P<0.0001 for both the susceptible and the
resistant congenic line; Figure 3F). For comparison,
Fbxo10 transcript levels in conA-stimulated T cells were
not different (P=0.45) when compared to the unstimu-
lated cultured T-cell samples from the susceptible congenic
control line, but were increased ( 1.5-fold, P=0.003) in
the resistant congenic line (Figure 3D). It should also be
noted that Frmpd1 failed to amplify in TaqMan assays on
primary, cultured unstimulated and cultured activated
T-cell samples (data not shown).
Taken together, the gene expression data implicate that
lower Fbxo10 transcript levels, and not Frmpd1 and
Tomm5 transcript levels in the immune system are
associated with the Mcs5a resistant allele. Furthermore,
these data suggest that Tomm5 and not Fbxo10 and
Frmpd1 may play a role in T-cell activation.
The TSS cluster of FBXO10/Fbxo10 is located in
MCS5A1
To understand the regulation of the Fbxo10/FBXO10 gene
it is important to know the exact TSS. This facilitates lo-
calization of the putative promoter. Two areas of tran-
scriptional initiation of the Fbxo10/FBXO10 gene in rats
and humans are annotated in the UCSC genome browser,
namely the CpG island in Mcs5a1/MCS5A1 and an area
close to the Mcs5a1/MCS5A1–Mcs5a2/MCS5A2 border
(Figure 4A). To identify the TSS of the Fbxo10 gene, we
performed the 50 RLM-RACE assay (RNA Ligase
Mediated-Rapid Ampliﬁcation of cDNA Ends). The
assay makes use of an RNA adapter that is ligated to
the de-CAP-ped 50-end of transcripts, followed by a RT
reaction to make cDNA. To amplify just the 50-ends of the
Fbxo10 gene, a nested PCR reaction was performed with
primers annealing to the translational start codon (ATG)-
containing exon and universal primers annealing to the 50
RNA-adapter. The assay was done on pools of thymus or
spleen RNA from four susceptible congenic control and
four Mcs5a resistant congenic rats and on human RNA
samples from thymus, spleen and breast tissue. A typical
PCR product yielded multiple bands on an agarose gel,
indicative of multiple TSSs. In total, 150 rat and 54 human
TSS clones were sequenced to elucidate the exact start
position of the Fbxo10/FBXO10 transcripts. In the rat,
14 TSS positions were found, all located in the CpG
island of the Mcs5a1 locus (Figure 4B). In the human,
three TSS positions were found, again, located in the
CpG island of the MCS5A1 locus (Figure 4B). It should
be noted that in the human breast RNA sample the
FBXO10 TSS cluster was found to be located close to
the MCS5A1-MCS5A2 border, indicating that the assay
was able to identify such cases. Identiﬁcation of the
Fbxo10/FBXO10 TSS cluster in the CpG island of
Mcs5a1/MCS5A1 suggests that potential regulatory
elements (e.g. promoter or enhancers) may be located
in the same region. The human TSS cluster is located
within 150bp of SNP rs6476643 (Figure 4B), which is
one of the breast cancer risk-associated SNPs found in
MCS5A1 (5).
140 Nucleic Acids Research, 2012,Vol. 40,No. 1Figure 3. Lower Fbxo10 transcript level in T cells is associated with the mammary carcinoma resistance phenotype mediated by Mcs5a.( A) The
thymic Fbxo10, and not splenic Frmpd1 transcript level is associated with the resistant Mcs5a allele. Graphed are average±SEM thymic Fbxo10
(dark gray) and splenic Frmpd1 (light gray) transcript levels (normalized to Gapdh) scaled to the thymic Fbxo10 or splenic Frmpd1 transcript level of
the susceptible congenic control line. Signiﬁcantly (P<0.05) different Fbxo10 and Frmpd1 transcript levels as compared with the susceptible congenic
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(continued)Reporter constructs identify functional interactions
between the MCS5A1 and MCS5A2 risk-associated
polymorphisms
In rat T cells, the Fbxo10 transcript level is under control
of the synthetically interacting resistant Mcs5a genetic
elements. This observation led to the hypothesis that the
polymorphisms of the resistant risk-associated alleles of
MCS5A1 and MCS5A2 could interact similarly to
downregulate FBXO10 transcript levels in human T
cells. To investigate this, Luciferase reporter assays were
performed using a series of constructs containing selected
MCS5A1 and MCS5A2 alleles. All constructs described
below were visually inspected by restriction enzyme
digest to ensure integrity (Supplementary Figure S2). A
human T-lymphocytic cell line (JURKAT) was transiently
transfected with each construct in the presence of a Renilla
expressing vector as a control for transfection efﬁciency.
First, a 1464-bp fragment of MCS5A1 including the
previously identiﬁed FBXO10 TSS cluster was inserted
upstream of the Luciferase (Luc
+) reporter gene in the
pGL3-basic vector (Figure 5A). Two versions of the con-
struct were made (Figure 5B), one containing the resistant
(R) allele of rs6476643 (G) and one containing the suscep-
tible (S) allele of rs6476643 (T). The transcriptional
activity of the R and S version of the FBXO10
TSS-Luciferase construct is not signiﬁcantly different
(P=0.45; Figure 5C).
Subsequently, the R and S FBXO10 TSS-Luciferase
constructs were modiﬁed to harbor MCS5A2 fragments
containing the resistant or susceptible allele of one or
two MCS5A2 SNPs (Figure 5A). The MCS5A2 fragments
were inserted downstream of Luc
+ (Figure 5B). The 15
correlated MCS5A2 polymorphisms were integrated into
10 MCS5A2 fragments of on average  990bp in length
(Supplementary Table S2). This yielded a series of 10 con-
structs, each present in two versions, namely SNP
rs6476643 susceptible plus MCS5A2 susceptible (SS) and
SNP rs6476643 resistant plus MCS5A2 resistant (RR).
The transcriptional activity of the entire series of 10 RR
constructs is signiﬁcantly lower compared to the entire
series of 10 SS combination constructs (Wilcoxon rank
test P<10
 48; Figure 5D).
Next, the transcriptional activity of the SS and RR
versions was compared for each construct (Figure 5D).
The transcriptional activity was not signiﬁcantly different
between the SS and RR versions of constructs 1, 2, 5, 7, 8
(P>0.05, Supplementary Table S2). However, the activity
of constructs 3, 4, 6, 9 and 10 were signiﬁcantly lower in
the RR version compared to the SS version (P<0.05,
Supplementary Table S2). In addition, the MCS5A2
SNPs rs62534439 (from construct 4), and rs62534443
and rs62534444 (from constructs 5 and 6) were also rep-
resented in constructs 4a and 5a, respectively, again result-
ing in lower activities for the RR versions compared to the
SS versions (Supplementary Figure S3), although only
signiﬁcant for construct 4a (P<0.05, Supplementary
Table S2).
The MCS5A2 fragments in construct 4, 6 and 10
(yielding lower activity in the RR combination constructs)
were also tested on their own for transcriptional activity
by transferring them to the cloning site upstream of Luc
+
(instead of the FBXO10 TSS-containing fragment). All of
these constructs had lower transcriptional activity as
compared with the FBXO10 TSS-containing fragment
(Supplementary Figure S4). The S and R version of
these constructs were not signiﬁcantly different
(Supplementary Figure S4), suggesting that the R allele
of the polymorphisms in these fragments act only when
combined with the R allele of the MCS5A1 SNP
rs6476643 in the FBXO10 TSS-containing fragment. The
observation that the MCS5A1 and MCS5A2 R alleles
functionally interact to downregulate transcriptional
activity is consistent with our observation of lower
Fbxo10 transcript levels in T cells of Mcs5a resistant
congenic animals compared to susceptible congenic
control animals.
Figure 3. Continued
control line are indicated with one and two asterisks, respectively. Sample sizes were: susc., n=9; Mcs5a, n=6; Mcs5a1, n=9; Mcs5a2, n=8.
(B) Lower Fbxo10 transcript level associated with the resistant Mcs5a allele is observed in unsorted and sorted thymocytes, except for double
negative (CD4
 CD8
 ) thymocytes. Graphed are average±SEM Fbxo10 transcript levels (normalized to Gapdh) in unsorted and sorted thymocytes,
scaled to the average Fbxo10 transcript level for the unsorted thymocytes of the susceptible congenic control line. Sample sizes for the susceptible
congenic control line and Mcs5a congenic resistant line were, respectively: unsorted, n=16 and n=9; CD4
 CD8
 , n=4 and n=4; CD4
+CD8
+,
n=17 and n=19; CD4
+CD8
 , n=15 and n=18; CD8
+CD4
 , n=18 and n=17. (C) Lower Fbxo10 transcript level associated with the resistant
Mcs5a allele is observed in splenic T cells, but not in other splenocytes. Graphed are average±SEM Fbxo10 transcript levels (normalized to Gapdh)
in unsorted and sorted splenocytes, scaled to the Fbxo10 transcript level for the unsorted splenocytes of the susceptible congenic control line. Sample
sizes for the susceptible congenic control line and Mcs5a resistant congenic line were, respectively: unsorted, n=16 and n=12; B cells, n=9 and
n=8; T cells, n=16 and n=13; non-B-/non-T cells, n=3 and n=5. (D) Lower Fbxo10 transcript level associated with the resistant Mcs5a allele is
observed in cultured unstimulated and conA-stimulated T cells. Graphed are average±SEM Fbxo10 transcript levels (normalized to ActB)i n
cultured T cells, unstimulated ( ) and stimulated (+) with conA, scaled to the average Fbxo10 transcript level of the unstimulated sample of the
susceptible congenic control line. Sample sizes for the susceptible congenic control line and Mcs5a resistant congenic line were, respectively:
unstimulated, n=11 and n=10; conA-stimulated, n=11 and n=12. (E) Tomm5 transcript levels in the immune system are not associated with
the resistant Mcs5a allele. Graphed are average±SEM Tomm5 transcript levels (normalized to ActB) in spleen, thymus and primary T cells, scaled
to the average Tomm5 transcript level of the susceptible congenic control line. Sample sizes for the susceptible congenic control line and Mcs5a
resistant congenic line were, respectively: spleen, n=7 and n=7; thymus, n=8 and n=8; primary T cells, n=12 and n=9. (F) Tomm5 transcript
levels in cultured T cells are strongly increased after conA-stimulation. Graphed are average±SEM Tomm5 transcript levels (normalized to ActB)i n
cultured T cells, unstimulated and stimulated with conA, scaled to the average Tomm5 transcript level of the unstimulated sample of the susceptible
congenic control line. Sample sizes for the susceptible congenic control line and Mcs5a resistant congenic line were, respectively: unstimulated, n=11
and n=10; conA-stimulated, n=11 and n=12. In B–F, signiﬁcantly different transcript level (P<0.05) between the susceptible congenic control
line (susc.; open bars) and the Mcs5a resistant congenic line (Mcs5a; ﬁlled bars) are indicated with an asterisk. In D and F, signiﬁcantly different
Fbxo10 or Tomm5 transcript level (P<0.05) between samples without and with conA stimulation is indicated with two asterisks.
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MCS5A/Mcs5a is a human/rat-conserved breast cancer
susceptibility locus. In the rat, the resistant Mcs5a allele
has previously been shown to consist of two interacting
genetic elements that must be located on the same
chromosome to elicit mammary carcinoma resistance (5).
The carcinoma susceptibility phenotype of Mcs5a is not
transferable from donor to recipient animals in a
mammary gland transplantation assay, indicating that
Mcs5a acts in a non-mammary cell-autonomous fashion
(15). We have also demonstrated that carcinoma develop-
ment is inﬂuenced by the immune system, as Mcs5a resist-
ant congenic rats reconstituted with the susceptible
congenic control line’s immune system develop more
mammary carcinomas as compared with Mcs5a resistant
congenic rats reconstituted with their own immune
system. Finally, we have observed that T-cell homeo-
stasis and functions are under control of the Mcs5a
locus (15).
In this study, we begin to translate the association of
genetic variants with the complex trait breast cancer sus-
ceptibility into molecular mechanisms. As the genetic
variants underlying the MCS5A/Mcs5a locus are found
in non-protein-coding sequences, we sought to investigate
the gene regulatory function of MCS5A/Mcs5a.W e
showed previously that the expression level of genes
located within 1 Mb surrounding the locus, including
Fbxo10, Frmpd1 and Tomm5 that are (partially) located
within Mcs5a, were not differentially expressed in the
Figure 4. Fbxo10/FBXO10 TSS analysis by the 50 RLM-RACE assay. (A) Schematic representation of three putative Fbxo10/FBXO10 transcripts
annotated in the UCSC genome browser, indicated relative to the position of the Mcs5a1/MCS5A1 locus (in black). The location of the Fbxo10/
FBXO10 speciﬁc primers in the ﬁrst coding exon is indicated (P). The 50 RLM-RACE revealed a cluster of 14 rat Fbxo10 TSSs within the Mcs5a1
CpG island (indicated in light gray). A cluster of three human FBXO10 TSSs in the orthologous MCS5A1 CpG island (indicated in light gray) was
identiﬁed. The position of the ﬁrst non-coding exon of Fbxo10/FBXO10 within the CpG island is indicated in dark gray. The human TSS cluster was
found to be located at 150-bp distance from breast cancer risk-associated SNP rs6476643. The transcripts not identiﬁed in rat or human immune
tissue are indicated with a X. (B) Sequence information of the rat and human Mcs5a1/MCS5A1 CpG island, ﬁrst non-coding Fbxo10/FBXO10 exon
(highlighted in gray) and TSS identiﬁed (in bold). In the human sequence, the breast cancer risk-associated SNP rs6476643 (T/G) is indicated.
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assays. (A) Schematic representation of the position of the genomic fragments derived from the MCS5A1 and MCS5A2 loci combined into
the Luciferase constructs. The MCS5A1 and MCS5A2 loci are shown as black lines. The light gray bars within the black lines represent the
CpG islands located in the locus. The three genes FBXO10, FRMPD1 and TOMM5 are shown in dark gray. The breast cancer risk-associated
polymorphisms are represented as vertical gray lines. The fragments subcloned into the reporter constructs are indicated as horizontal light gray bars.
The susceptible alleles of the MCS5A2 polymorphisms were combined with the susceptible allele of the MCS5A1 SNP rs6476643 (SS constructs
1–10). Similarly, the resistant alleles were combined (RR constructs 1–10). (B) Map of the FBXO10 TSS-Luciferase reporter construct. A MCS5A1
fragment containing the FBXO10 TSSs and the risk-associated SNP rs6476643 was inserted upstream of the Luciferase reporter gene (Luc
+) in reverse
genomic orientation. Two versions of the construct were created, namely having the susceptible (S; T allele) or resistant (R; G allele) of
SNP rs6476643. Other features of the construct include the ampicillin resistance gene (Amp
R), origin of replication derived from ﬁlamentous
phage (f1 ori), origin of replication in E. coli (ori), a synthetic poly(A) signal/transcriptional pause site for background reduction [synthetic
poly(A)] and a cloning site downstream of Luc
+.( C) Box plot of the relative Luciferase activity of the R and S constructs. n=30 transient
transfection assays. (D) Average±SEM relative Luciferase activity of constructs SS 1–10 and RR 1–10. On the x-axis, the genomic distance of
the MCS5A2 polymophisms to the MCS5A1 SNP rs6476643 is plotted. The data points at genomic distance 0 correspond to the FBXO10
TSS-Luciferase constructs S and R. The measurements indicated with an asterisk are signiﬁcantly different between SS and RR (P<0.05).
The entire series of RR1–10 is signiﬁcantly lower as compared with the entire series of SS 1–10 (P<10
 48). n=6 or more transient transfection
assays per data point.
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Mcs5a resistant congenic rats. Two of these genes,
however, were found to be differentially expressed in the
immune system, namely Fbxo10 in the thymus, and
Frmpd1 in the spleen (5). Here, we have shown that the
genetic interaction that is necessary for the mammary car-
cinoma resistance phenotype, is also essential to
downregulate Fbxo10 transcript levels in the thymus.
The transcript levels of Frmpd1 and Tomm5 were not dif-
ferentially associated with the Mcs5a alleles. Lower
Fbxo10 transcript levels in the resistant congenic rat line
as compared with the susceptible congenic control line
were detectable in CD4
+CD8
  thymocytes, CD8
+CD4
 
thymocytes, CD4
+CD8
+ thymocytes and CD3
+ primary,
cultured unstimulated and cultured activated T cells from
the spleen. Analysis of some aspects of the gene regulatory
mechanism mediated by the Mcs5a/MCS5A locus
revealed striking similarities between rats and humans.
First, the TSSs of the Fbxo10/FBXO10 transcripts were
found to be located in the CpG island in Mcs5a1/
MCS5A1 in both rat and human thymus and spleen
RNA samples. The human FBXO10 TSS cluster was
found to be located 150-bp away from a breast cancer
risk-associated SNP (rs6476643). Second, both the rat
and human Mcs5a/MCS5A locus display a similar
proﬁle of chromatin looping and CTCF/cohesin binding.
Third, functional assessment of the transcriptional regula-
tory properties of the resistant (R) and susceptible (S)
allele of rs6476643 in combination with the R and S
allele of each of the 15 MCS5A2 risk-associated SNPs,
revealed an overall signiﬁcantly lower transcriptional
activity for the RR combinations compared to the SS
combinations, thus mimicking the resistant Mcs5a1–
Mcs5a2 interaction controlling Fbxo10 transcript levels
and mammary carcinoma resistance in the rat.
Interestingly, the R allele of multiple MCS5A2 SNPs
combined with the R allele of rs6476643 can
independently lower transcriptional activity compared to
the combined SS alleles, perhaps underlying a haplotype
effect between the MCS5A1 and MCS5A2 breast cancer
risk-associated polymorphisms, which are separated by
>60kb in the genome. Physical interactions between the
fragments containing the MCS5A1 and MCS5A2
risk-associated polymorphisms, however, were not
directly observed, likely due to limited sensitivity of the
3C assay and the transient, stochastic and/or structurally
diffuse nature of the putative interactions.
Mcs5a/MCS5A harbors a higher order chromatin struc-
ture, which spatially isolates the Tomm5/TOMM5 gene
and its ﬂanking regulatory region by locating them
within the loop (Figure 6). The chromatin loop also func-
tionally isolates Tomm5 as its transcript level was found to
be strongly upregulated in T-cell activation, whereas
Fbxo10 or Frmpd1 transcript levels were not. The higher
order chromatin structure is thought to be an insulator
loop. There appear to be three looping fragments
involved that are all bound by CTCF and cohesin.
CTCF has been recognized as a DNA-binding protein
with diverse functions (23), for example insulator loop
formation (24), and enhancer–promoter looping, e.g. in
the b-globin locus (25). CTCF has also been associated
with boundary/barrier elements, which demarcate separ-
ately regulated chromatin domains (26). The transcription
of a growing number of genes has been found to be de-
pendent on CTCF- and/or cohesin-binding and -looping.
For example, gene expression in the developmentally
regulated HoxA cluster is under control of CTCF-
mediated heterochromatin partitioning, with involvement
of Oct4 and cohesin loading at the CTCF site in undiffer-
entiated embryonic stem cells and differentiated neuronal
progenitor cells, respectively (27). Another example of
CTCF-mediated looping and cooperation of a transcrip-
tion factor (T-bet) in cell type speciﬁc gene transcription is
the Th1 cell-speciﬁc expression of Ifng (28). Ablation of
Figure 6. A model of the MCS5A locus in a folded conﬁguration. The ﬁrst (non-coding, 50-UTR) and second (coding, ATG-containing) exons of the
FBXO10 transcript are displayed in orange. The TOMM5 transcript is indicated in dark blue. The ﬁrst (non-coding, 50-UTR) exon of the FRMPD1
transcript is shown in light blue. The CpG islands associated with their promoters are indicated in dark green. The correlated polymorphisms that
associate with breast cancer risk are depicted as purple bars. The looping fragments are shown in light green and are shown to be bound by CTCF.
In this model, the breast cancer susceptibility locus MCS5A harbors an insulator loop encompassing the TOMM5 gene and regulatory region. The
looped structure involves three elements that may loop simultaneously (as depicted) or loop in speciﬁc combinations in a single nucleus. The
polymorphisms associated with breast cancer risk in MCS5A1 and MCS5A2 are located at both sides of the looped structure and are in closer
proximity as may be derived from a linear genome view. We hypothesize that the MCS5A1 and MCS5A2 breast cancer risk variants interact to
regulate the transcript levels of FBXO10.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 145the Mcs5a loop by depletion of CTCF yielded a lower
Tomm5 transcript level (whereas the transcript levels of
two other genes adjacent to Mcs5a were unaffected),
possibly through misregulation by the adjacently located
repressed chromatin (upstream of the untranscribed
Frmpd1 gene), which would classify the insulator loop as
a boundary element/barrier loop. Since the looped frag-
ments were identiﬁed in all cell types and both (resistant
and susceptible) genotypes studied, it is currently unclear
if the loops occur simultaneously in a nucleus or if com-
binations of looping partners have distinct functions, such
as enhancer looping to the Tomm5/TOMM5 promoter, or
condition-dependent insulator looping.
We propose a model in which the risk-associated alleles
in MCS5A1 and MCS5A2 are located on either sides of
the loop, in closer physical proximity than may be implied
from a linear genome view, allowing them to interact. It is
currently unknown if the independently associating
human MCS5A1 and MCS5A2 alleles genetically
interact, as they do in the rat to modulate breast cancer
risk. This is due to the technical inability to phase these
alleles over the 60kb that separates them, in the double
heterozygous human case–control samples, which is the
majority of the samples. However, there is linkage disequi-
librium between the alleles, with the RR and SS double
homozygotes being overrepresented in the population
compared to the expected co-occurrences according to
Hardy–Weinberg equilibrium, suggesting a synthetic inter-
action (5).
While GWAS have successfully identiﬁed many
common variants associated with breast cancer suscepti-
bility, implications concerning their mechanisms of action
are limited. Two studies have implicated such breast
cancer risk loci in expression regulation of nearby genes,
namely loci close to FGFR2 (11) and COX11 (1). The
difﬁculties in identifying causative polymorphisms from
GWAS as well as their functions could be due to limited
structural and mechanistic knowledge regarding the cis-
acting polymorphisms and their possible interactions
within a locus (e.g. synthetic interactions underlying a
haplotype effect). Furthermore, the lack of knowledge of
which cell type(s) to use for functional studies can
compound these issues. Extending high-resolution com-
parative genomic studies to additional alleles, cell types,
and traits will provide useful models to help interpret the
results of GWAS ﬁndings. The results of this study
identify Fbxo10 as a strong candidate for driving the
mammary carcinoma resistance phenotype of the Mcs5a
locus likely via activities in T cells. In depth analysis of the
activities of speciﬁc T-cell populations regarding the
normal and transformed mammary epithelium of
congenic rat models and genetic manipulation of Fbxo10
will in the future elucidate more cellular and molecular
mechanisms underlying the Mcs5a breast cancer suscepti-
bility locus.
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